Jefferies Financial Group started coverage on shares of Phoenix Tree (NASDAQ:IMAB) in a report issued on Tuesday, Benzinga reports. The firm issued a buy rating and a $16.00 target price on the stock. Jefferies Financial Group also issued estimates for Phoenix Tree’s FY2020 earnings at ($1.92) EPS, FY2021 earnings at ($2.57) EPS, FY2022 earnings at ($2.66) EPS, FY2023 earnings at ($2.59) EPS and FY2024 earnings at ($1.65) EPS.
NASDAQ IMAB opened at $10.81 on Tuesday. Phoenix Tree has a one year low of $9.30 and a one year high of $15.79.
Phoenix Tree Company Profile
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases.
See Also: Balance Sheet
Receive News & Ratings for Phoenix Tree Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phoenix Tree and related companies with MarketBeat.com's FREE daily email newsletter.